Oleksandr Skarzhevskyi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Oleksandr Skarzhevskyi has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Dmytro Khomiakov
ДУ «Національний науковий центр “Інститут кардіології, клінічної та регенеративної медицини імені академіка М.Д. Стражеска” НАМН України», Київ
4 shared publications - Vitalii Kyryk
Strazhesko National Scientific Center of the National Academy of Medical Sciences of Ukraine, Institute of Genetic and Regenerative Medicine, Kyiv, Ukraine; D. F. Chebotarev State Institute of Gerontology of the National Academy of Medical Sciences of Ukraine, Laboratory of Pathophysiology and Immunology, Kyiv, Ukraine
4 shared publications - Alexander Parkhomenko
National Scientific Center «M.D. Strazhesko Institute of Cardiology, Clinical and Regenerative Medicine» of NAMS of Ukraine, Kyiv, Ukraine
3 shared publications - Alina Ustymenko
Strazhesko National Scientific Center of the National Academy of Medical Sciences of Ukraine, Institute of Genetic and Regenerative Medicine, Kyiv, Ukraine; D. F. Chebotarev State Institute of Gerontology of the National Academy of Medical Sciences of Ukraine, Laboratory of Pathophysiology and Immunology, Kyiv, Ukraine
3 shared publications - Oleg Tsupykov
Department of Cytology, Bogomoletz Institute of Physiology, Kyiv, Ukraine
3 shared publications - O. I. Irkin
ДУ «Національний науковий центр “Інститут кардіології, клінічної та регенеративної медицини імені академіка М.Д. Стражеска” НАМН України», Київ
2 shared publications
Latest Publications
- 20 November 2026
- Published by Institute of Cell Therapy in Cell and Organ Transplantology
- Vol. 14 (2)
Long-term alterations in cellular and humoral markers associated with senescence and regeneration in patients at high cardiovascular risk
Cellular senescence and the associated secretory phenotype may contribute to chronic inflammation, endothelial dysfunction, and impaired tissue repair, thereby limiting tissue regenerative capacity. This issue is of particular relevance to patients with cardiovascular disease who have been exposed to additional adverse stressors during the COVID-19 pandemic. Objective. To compare long-term changes in cellular and humoral markers associated with senescence and regeneration in patients at high cardiovascular risk who experienced acute cardiac events before and during the COVID-19 pandemic. Methods. The study included 90 patients allocated to three groups of 30: patients who had experienced myocardial infarction before the COVID-19 pandemic; patients with myocardial infarction accompanied by COVID-19 during the pandemic; and patients who had experienced myocardial infarction during the pandemic without concomitant COVID-19 at the time of hospitalization. At 61-73 months after the acute event, flow cytometry was used to determine the relative proportions of leukocytes expressing senescence-associated beta-galactosidase, CD34+ hematopoietic progenitor cells, CD309+ endothelial progenitor cells, and CD31hi circulating endothelial cells in peripheral blood. The proportion of cells containing senescence-associated heterochromatin foci was assessed in blood smears by fluorescence microscopy. The cytokinesis-block micronucleus assay was performed in short-term cultures of peripheral blood mononuclear cells. Serum concentrations of IL-1β, IL-6, ICAM-1, VCAM-1, TNF-α, von Willebrand factor (vWF), tissue plasminogen activator (tPA), lactate dehydrogenase A (LDHA), and endothelial nitric oxide synthase (eNOS) were measured using enzyme-linked immunosorbent assays. Results. The most pronounced between-group differences were observed in cellular parameters. Patients in both pandemic-period groups had higher proportions of SA-β-gal-positive leukocytes, CD309+ progenitor cells, and CD31hi circulating endothelial cells. The group with concomitant COVID-19 also showed a higher proportion of CD34+ hematopoietic progenitor cells in peripheral blood, together with increased frequencies of micronuclei and apoptotic cells in mononuclear cell cultures. In contrast, among the serum humoral markers, statistically significant between-group differences were detected only for IL-1β and von Willebrand factor. Conclusions. Long-term differences in selected cellular and humoral parameters associated with senescence, regeneration, and hemostasis were identified in patients following myocardial infarction. These differences varied according to the presence of concomitant COVID-19 and exposure to stress-related factors during the pandemic, highlighting the importance of a comprehensive assessment of these parameters in patients at high cardiovascular risk.
- 20 November 2026
- Published by Institute of Cell Therapy in Cell and Organ Transplantology
- Vol. 14 (2)
Long-term alterations in cellular and humoral markers associated with senescence and regeneration in patients at high cardiovascular risk
Cellular senescence and the associated secretory phenotype may contribute to chronic inflammation, endothelial dysfunction, and impaired tissue repair, thereby limiting tissue regenerative capacity. This issue is of particular relevance to patients with cardiovascular disease who have been exposed to additional adverse stressors during the COVID-19 pandemic. Objective. To compare long-term changes in cellular and humoral markers associated with senescence and regeneration in patients at high cardiovascular risk who experienced acute cardiac events before and during the COVID-19 pandemic. Methods. The study included 90 patients allocated to three groups of 30: patients who had experienced myocardial infarction before the COVID-19 pandemic; patients with myocardial infarction accompanied by COVID-19 during the pandemic; and patients who had experienced myocardial infarction during the pandemic without concomitant COVID-19 at the time of hospitalization. At 61-73 months after the acute event, flow cytometry was used to determine the relative proportions of leukocytes expressing senescence-associated beta-galactosidase, CD34+ hematopoietic progenitor cells, CD309+ endothelial progenitor cells, and CD31hi circulating endothelial cells in peripheral blood. The proportion of cells containing senescence-associated heterochromatin foci was assessed in blood smears by fluorescence microscopy. The cytokinesis-block micronucleus assay was performed in short-term cultures of peripheral blood mononuclear cells. Serum concentrations of IL-1β, IL-6, ICAM-1, VCAM-1, TNF-α, von Willebrand factor (vWF), tissue plasminogen activator (tPA), lactate dehydrogenase A (LDHA), and endothelial nitric oxide synthase (eNOS) were measured using enzyme-linked immunosorbent assays. Results. The most pronounced between-group differences were observed in cellular parameters. Patients in both pandemic-period groups had higher proportions of SA-β-gal-positive leukocytes, CD309+ progenitor cells, and CD31hi circulating endothelial cells. The group with concomitant COVID-19 also showed a higher proportion of CD34+ hematopoietic progenitor cells in peripheral blood, together with increased frequencies of micronuclei and apoptotic cells in mononuclear cell cultures. In contrast, among the serum humoral markers, statistically significant between-group differences were detected only for IL-1β and von Willebrand factor. Conclusions. Long-term differences in selected cellular and humoral parameters associated with senescence, regeneration, and hemostasis were identified in patients following myocardial infarction. These differences varied according to the presence of concomitant COVID-19 and exposure to stress-related factors during the pandemic, highlighting the importance of a comprehensive assessment of these parameters in patients at high cardiovascular risk.
- Open Access
- 30 October 2026
- Published by Chetverta Khvylia in Ukrainian Journal of Cardiology
- Vol. 33 (5) , 19-31
Раннє застосування левосимендану при декомпенсованій серцевій недостатності для кардіоренальної стабілізації та ініціації квадротерапії
Пацієнти, які надходять із декомпенсованою серцевою недостатністю (ДСН), мають значний ризик смерті та високу частоту ускладнень. Ці несприятливі наслідки можуть бути зменшені завдяки ранньому початку терапії та швидкому титруванню доз препаратів, що модифікують перебіг захворювання. Однак артеріальна гіпотензія, погана перфузія органів і діуретикорезистентність часто перешкоджають впровадженню цієї стратегії.Мета роботи – оцінити ефективність і безпечність застосування інодилататора левосимендану в межах комплексного лікування пацієнтів із ДСН, ускладненою ознаками гіпоперфузії або діуретикорезистентністю, а також дослідити можливість ранньої ініціації квадротерапії в цієї когорти хворих.Матеріали і методи. У проспективне одноцентрове когортне дослідження було залучено 48 пацієнтів із діагнозом ДСН і зниженою фракцією викиду лівого шлуночка (ФВ ЛШ). Середній вік пацієнтів становив (62,0±11,8) року, серед пацієнтів переважали чоловіки (70,8 %). Ішемічна хвороба серця була первинною етіологією серцевої недостатності у 54,1 % випадків. Лабораторні параметри (N-кінцевий фрагмент мозкового натрійуретичного пропептиду (NT-proBNP), креатинін, швидкість клубочкової фільтрації (CКD-EPI, 2021), С-реактивний білок, кількість лейкоцитів) та ехокардіографічні дані (ФВ ЛШ, глобальна поздовжня деформація, Е/e’, TAPSE) оцінювали на початку і через 72 год після початку інфузії левосимендану.Результати. Інфузія левосимендану привела до значного зниження середніх рівнів NT-proBNP з (8141,2±8224,7) до (3984,0±4402,3) пг/мл (p<0,01). Недостатню ефективність терапії (зниження NT-proBNP < 25 % або його підвищення) спостерігали у 29,2 % пацієнтів, що асоціювалося з вищими вихідними рівнями С-реактивного білка [(14,6±13,9) проти (5,7±6,1) мг/л, p=0,045] і кількості лейкоцитів [(10,3±3,4) проти (8,0±2,3) · 109/л, p=0,039]. Ехокардіографія показала значне покращання ФВ ЛШ [з (28,3±5,8) до (33,9±5,1) %, p=0,002] і глобальної поздовжньої деформації [з –(3,9±1,0) до –(6,4±1,1) %, p=0,048]. Водночас спостерігалося значне зниження співвідношення E/e’ – з 14,9±6,4 до 10,4±3,4 (p=0,035) – разом із позитивною тенденцією до покращання систолічної функції правого шлуночка (TAPSE; p=0,092) та зменшенням системного венозного застою. Посилення діурезу супроводжувалося сприятливим ренальним ефектом, про що свідчило значне зниження рівня креатиніну через 72 год [з вихідного рівня (109,9±31,3) до (99,9±21,6) мкмоль/л; p=0,03]. Клінічна стабілізація сприяла успішному початку квадротерапії перед виписуванням зі стаціонару в 39 (81,3 %) пацієнтів (антагоністи мінералокортикоїдних рецепторів – 97,9 %, бета-адреноблокатори – 97,9 %, інгібітори натрійзалежного котранспортера глюкози 2-го типу – 93,8 %, блокатори ренін-ангіотензинової системи – 91,7 %).Висновки. Залучення левосимендану до комплексного лікування пацієнтів з ДСН із діуретикорезистентністю або гіпоперфузією є ефективним і безпечним підходом. Він забезпечує потужні гемодинамічні і ренальні ефекти, значно покращує як систолічну, так і діастолічну функцію серця, зменшує застійні явища і створює сприятливе клінічне вікно для безпечного раннього початку квадротерапії відповідно до клінічних настанов.
- 30 October 2026
- Published by Chetverta Khvylia in Ukrainian Journal of Cardiology
- Vol. 33 (5) , 19-31
Open AccessРаннє застосування левосимендану при декомпенсованій серцевій недостатності для кардіоренальної стабілізації та ініціації квадротерапії
Пацієнти, які надходять із декомпенсованою серцевою недостатністю (ДСН), мають значний ризик смерті та високу частоту ускладнень. Ці несприятливі наслідки можуть бути зменшені завдяки ранньому початку терапії та швидкому титруванню доз препаратів, що модифікують перебіг захворювання. Однак артеріальна гіпотензія, погана перфузія органів і діуретикорезистентність часто перешкоджають впровадженню цієї стратегії.Мета роботи – оцінити ефективність і безпечність застосування інодилататора левосимендану в межах комплексного лікування пацієнтів із ДСН, ускладненою ознаками гіпоперфузії або діуретикорезистентністю, а також дослідити можливість ранньої ініціації квадротерапії в цієї когорти хворих.Матеріали і методи. У проспективне одноцентрове когортне дослідження було залучено 48 пацієнтів із діагнозом ДСН і зниженою фракцією викиду лівого шлуночка (ФВ ЛШ). Середній вік пацієнтів становив (62,0±11,8) року, серед пацієнтів переважали чоловіки (70,8 %). Ішемічна хвороба серця була первинною етіологією серцевої недостатності у 54,1 % випадків. Лабораторні параметри (N-кінцевий фрагмент мозкового натрійуретичного пропептиду (NT-proBNP), креатинін, швидкість клубочкової фільтрації (CКD-EPI, 2021), С-реактивний білок, кількість лейкоцитів) та ехокардіографічні дані (ФВ ЛШ, глобальна поздовжня деформація, Е/e’, TAPSE) оцінювали на початку і через 72 год після початку інфузії левосимендану.Результати. Інфузія левосимендану привела до значного зниження середніх рівнів NT-proBNP з (8141,2±8224,7) до (3984,0±4402,3) пг/мл (p<0,01). Недостатню ефективність терапії (зниження NT-proBNP < 25 % або його підвищення) спостерігали у 29,2 % пацієнтів, що асоціювалося з вищими вихідними рівнями С-реактивного білка [(14,6±13,9) проти (5,7±6,1) мг/л, p=0,045] і кількості лейкоцитів [(10,3±3,4) проти (8,0±2,3) · 109/л, p=0,039]. Ехокардіографія показала значне покращання ФВ ЛШ [з (28,3±5,8) до (33,9±5,1) %, p=0,002] і глобальної поздовжньої деформації [з –(3,9±1,0) до –(6,4±1,1) %, p=0,048]. Водночас спостерігалося значне зниження співвідношення E/e’ – з 14,9±6,4 до 10,4±3,4 (p=0,035) – разом із позитивною тенденцією до покращання систолічної функції правого шлуночка (TAPSE; p=0,092) та зменшенням системного венозного застою. Посилення діурезу супроводжувалося сприятливим ренальним ефектом, про що свідчило значне зниження рівня креатиніну через 72 год [з вихідного рівня (109,9±31,3) до (99,9±21,6) мкмоль/л; p=0,03]. Клінічна стабілізація сприяла успішному початку квадротерапії перед виписуванням зі стаціонару в 39 (81,3 %) пацієнтів (антагоністи мінералокортикоїдних рецепторів – 97,9 %, бета-адреноблокатори – 97,9 %, інгібітори натрійзалежного котранспортера глюкози 2-го типу – 93,8 %, блокатори ренін-ангіотензинової системи – 91,7 %).Висновки. Залучення левосимендану до комплексного лікування пацієнтів з ДСН із діуретикорезистентністю або гіпоперфузією є ефективним і безпечним підходом. Він забезпечує потужні гемодинамічні і ренальні ефекти, значно покращує як систолічну, так і діастолічну функцію серця, зменшує застійні явища і створює сприятливе клінічне вікно для безпечного раннього початку квадротерапії відповідно до клінічних настанов.
- Open Access
- 27 February 2026
- Published by Chetverta Khvylia in Ukrainian Journal of Cardiology
- Vol. 33 (1) , 7-19
Негативний вплив поєднання гострого інфаркту міокарда, активного COVID-19 та факторів, асоційованих із воєнним часом, на особливості віддаленого післяінфарктного періоду
The aim – to identify markers of long-term cardiovascular risk in patients with acute myocardial infarction (AMI) with concomitant active COVID-19 and in patients with AMI during wartime, and to evaluate the impact of these factors on the course of the post-infarction period.Materials and methods. A cohort of 160 patients with AMI was examined (mean age 64 years; 78 % men). The first group (n=80) was treated before the COVID-19 pandemic and served as a control group. The second group (n=31) was treated during the pandemic with active concomitant SARS-CoV-2 infection. The third group (n=49) was treated during wartime in Ukraine and had no active COVID-19 infection. All patients received standard in-hospital treatment according to current guidelines with appropriate clinical and laboratory evaluation. Patients who died during hospitalization were excluded. All enrolled patients underwent a 2-year follow-up. Outcomes included all-cause mortality, major cardiovascular events, and a composite endpoint of death or cardiovascular events.Results and discussion. Patients with concomitant COVID-19 demonstrated a higher rate of long-term mortality (19.4 % vs 7.5 % in controls, p=0.1), whereas patients with AMI during wartime had the highest rate of nonfatal cardiovascular events (46.9 % vs 27.5 % in controls, p 15 % on day 1 of AMI and > 18 % on days 5–10), as well as a composite scale incorporating in-hospital lymphocyte percentages, total bilirubin, and HDL cholesterol measured on day 1 (sensitivity 91.7 %, specificity 87.5 %, p 2 significant (> 70 %) or > 3 total coronary stenoses (sensitivity 76.2 %, specificity 95 %, p<0.001).Conclusions. In AMI patients, concomitant COVID-19 is associated with increased long-term mortality, while wartime factors increase long-term risk primarily through nonfatal cardiovascular events. These effects on the post-infarction period are linked to maladaptive inflammatory and stress responses to myocardial injury, reflected in specific clinical and laboratory changes. Unlike the previously widely used neutrophil-to-lymphocyte ratio, these markers allow individualized assessment of long-term cardiovascular risk in these patients.
- 27 February 2026
- Published by Chetverta Khvylia in Ukrainian Journal of Cardiology
- Vol. 33 (1) , 7-19
Open AccessНегативний вплив поєднання гострого інфаркту міокарда, активного COVID-19 та факторів, асоційованих із воєнним часом, на особливості віддаленого післяінфарктного періоду
The aim – to identify markers of long-term cardiovascular risk in patients with acute myocardial infarction (AMI) with concomitant active COVID-19 and in patients with AMI during wartime, and to evaluate the impact of these factors on the course of the post-infarction period.Materials and methods. A cohort of 160 patients with AMI was examined (mean age 64 years; 78 % men). The first group (n=80) was treated before the COVID-19 pandemic and served as a control group. The second group (n=31) was treated during the pandemic with active concomitant SARS-CoV-2 infection. The third group (n=49) was treated during wartime in Ukraine and had no active COVID-19 infection. All patients received standard in-hospital treatment according to current guidelines with appropriate clinical and laboratory evaluation. Patients who died during hospitalization were excluded. All enrolled patients underwent a 2-year follow-up. Outcomes included all-cause mortality, major cardiovascular events, and a composite endpoint of death or cardiovascular events.Results and discussion. Patients with concomitant COVID-19 demonstrated a higher rate of long-term mortality (19.4 % vs 7.5 % in controls, p=0.1), whereas patients with AMI during wartime had the highest rate of nonfatal cardiovascular events (46.9 % vs 27.5 % in controls, p 15 % on day 1 of AMI and > 18 % on days 5–10), as well as a composite scale incorporating in-hospital lymphocyte percentages, total bilirubin, and HDL cholesterol measured on day 1 (sensitivity 91.7 %, specificity 87.5 %, p 2 significant (> 70 %) or > 3 total coronary stenoses (sensitivity 76.2 %, specificity 95 %, p<0.001).Conclusions. In AMI patients, concomitant COVID-19 is associated with increased long-term mortality, while wartime factors increase long-term risk primarily through nonfatal cardiovascular events. These effects on the post-infarction period are linked to maladaptive inflammatory and stress responses to myocardial injury, reflected in specific clinical and laboratory changes. Unlike the previously widely used neutrophil-to-lymphocyte ratio, these markers allow individualized assessment of long-term cardiovascular risk in these patients.
- Open Access
- 1 January 2026
- Published by Wiley in BioMed Research International
- Vol. 2026 (1) , 5553698
Analysis of Cytological Markers of Cellular Senescence in High‐Risk Cardiovascular Patients After COVID‐19
The purpose of this study was to investigate cytological markers of cellular senescence—including senescence‐associated β ‐galactosidase (SA‐ β ‐gal), senescence‐associated heterochromatin foci (SAHF), and parameters of the cytokinesis‐block micronucleus (CBMN) cytome assay—in peripheral blood samples from patients who had experienced an acute coronary syndrome accompanied by COVID‐19 (Group 2), compared with similar patients without COVID‐19 (Group 1). The relative proportion of SA‐ β ‐gal–positive leukocytes was approximately threefold higher in patients with a history of COVID‐19 compared with Group 1. Group 2 also demonstrated a significantly higher frequency of SAHF‐positive leukocytes. According to the CBMN assay, Group 2 showed a significantly higher relative content of binucleated leukocytes with micronuclei, as well as a higher frequency of apoptotic mononuclear cells. No significant differences were observed between the groups in the relative content of binucleated cells with nuclear buds or nucleoplasmic bridges, nor in the proportion of necrotic mononuclear cells. The cytokinesis‐block proliferation index was comparable between the groups. The findings of this retrospective study may indicate a detrimental long‐term effect of COVID‐19 on the manifestation of cellular senescence at the organismal level, and the evaluated markers may be informative for developing new prognostic strategies for this patient population.
- 1 January 2026
- Published by Wiley in BioMed Research International
- Vol. 2026 (1) , 5553698
Open AccessAnalysis of Cytological Markers of Cellular Senescence in High‐Risk Cardiovascular Patients After COVID‐19
The purpose of this study was to investigate cytological markers of cellular senescence—including senescence‐associated β ‐galactosidase (SA‐ β ‐gal), senescence‐associated heterochromatin foci (SAHF), and parameters of the cytokinesis‐block micronucleus (CBMN) cytome assay—in peripheral blood samples from patients who had experienced an acute coronary syndrome accompanied by COVID‐19 (Group 2), compared with similar patients without COVID‐19 (Group 1). The relative proportion of SA‐ β ‐gal–positive leukocytes was approximately threefold higher in patients with a history of COVID‐19 compared with Group 1. Group 2 also demonstrated a significantly higher frequency of SAHF‐positive leukocytes. According to the CBMN assay, Group 2 showed a significantly higher relative content of binucleated leukocytes with micronuclei, as well as a higher frequency of apoptotic mononuclear cells. No significant differences were observed between the groups in the relative content of binucleated cells with nuclear buds or nucleoplasmic bridges, nor in the proportion of necrotic mononuclear cells. The cytokinesis‐block proliferation index was comparable between the groups. The findings of this retrospective study may indicate a detrimental long‐term effect of COVID‐19 on the manifestation of cellular senescence at the organismal level, and the evaluated markers may be informative for developing new prognostic strategies for this patient population.
- Open Access
- 26 December 2025
- Published by Chetverta Khvylia in Ukrainian Journal of Cardiology
- Vol. 32 (6) , 7-18
Вплив перенесеного супутнього захворювання на COVID-19 у пацієнтів з гострим інфарктом міокарда на функцію ендотелію, маркери системного запалення і субпопуляції клітин крові у віддаленому періоді спостереження
The aim – to assess the course of the coronary artery disease (CAD), the state of endothelial function, intracardiac hemodynamics, and immune system response in the long term follow-up period after ST-elevation myocardial infarction (STEMI) in patients with concomitant COVID-19 for the development of personalized treatment approaches. Materials and methods. A cohort of patients with CAD (n=60; 85.0 % men; mean age 61.0±1.3 years) was examined 40-48 months after STEMI. Group 1 included patients treated in 2019 before the COVID-19 pandemic (n=30), and group 2 included patients treated during the pandemic in 2020–2022 (n=30) who had documented SARS-CoV-2 infection. The study excluded patients with diabetes mellitus, chronic kidney disease, cancer, chronic inflammatory diseases, high-grade chronic heart failure, and anemia. The examined sample was obtained through screening of 807 patients. All patients underwent a set of clinical, laboratory, and instrumental examinations, which included medical history collection (documented COVID-19 episodes, vaccination history, CAD exacerbations, treatment), cardiac ultrasound, endothelium-dependent vasodilation (EDVD) testing, general laboratory tests, and immunophenotyping of blood cell subpopulations by flow cytometry using the markers CD3, CD4, CD8, CD31, CD34, CD38, and CD309.Results. Patients in the examined groups did not differ in age or baseline clinical and anamnestic characteristics (including the frequency of documented COVID-19 and vaccination history), and all demonstrated high adherence to treatment. According to EDVD test, endothelial dysfunction was detected in 70 % of patients in both groups, and the mean test values were comparable. Biochemical blood parameters also showed no differences between the groups, nor did inflammatory markers such as C-reactive protein, erythrocyte sedimentation rate, the neutrophil-to-lymphocyte ratio, and the platelet-to-lymphocyte ratio. Correlation analysis of EDVD with inflammatory markers did not reveal any significant associations.However, immunophenotyping of blood cell subpopulations demonstrated significant differences between the groups. In group 2 patients, who had STEMI with concomitant COVID-19, lower levels of T lymphocytes and higher numbers of immature T-cell were observed, while the levels of T-helpers, T-suppressors, and their ratio did not differ from those in group 1. At the same time, the number of hematopoietic progenitor cells, activated T- and B-lymphocytes, as well as cells expressing vascular endothelial growth factor (VEGF) receptors, were increased. In this group, no significant correlations were found between EDVD results and any clinical, laboratory, or instrumental parameters, nor with the results of blood cell subpopulation phenotyping. When comparing subgroups of patients with markedly reduced endothelial function (values below the group mean), group 2 showed higher monocyte counts, lower lymphocyte counts, increased populations of activated T- and B-lymphocytes and immature T-lymphocytes, together with elevated levels of repair markers (CD309+ endothelial progenitors), while markers of endothelial activation and damage remained unchanged.Conclusions. A study conducted in a carefully selected cohort of patients with CAD who had previously experienced STEMI revealed the negative consequences of its combination with COVID-19. Despite similar clinical, instrumental, and laboratory characteristics between the groups, patients with concomitant COVID-19 demonstrated impaired mechanisms of endothelial function regulation and immune system dysfunction, characterized by the development of a pro-inflammatory cellular phenotype. These changes occurred against the background of vascular injury and were accompanied by secondary activation of proangiogenic reparative potential.
- 26 December 2025
- Published by Chetverta Khvylia in Ukrainian Journal of Cardiology
- Vol. 32 (6) , 7-18
Open AccessВплив перенесеного супутнього захворювання на COVID-19 у пацієнтів з гострим інфарктом міокарда на функцію ендотелію, маркери системного запалення і субпопуляції клітин крові у віддаленому періоді спостереження
The aim – to assess the course of the coronary artery disease (CAD), the state of endothelial function, intracardiac hemodynamics, and immune system response in the long term follow-up period after ST-elevation myocardial infarction (STEMI) in patients with concomitant COVID-19 for the development of personalized treatment approaches. Materials and methods. A cohort of patients with CAD (n=60; 85.0 % men; mean age 61.0±1.3 years) was examined 40-48 months after STEMI. Group 1 included patients treated in 2019 before the COVID-19 pandemic (n=30), and group 2 included patients treated during the pandemic in 2020–2022 (n=30) who had documented SARS-CoV-2 infection. The study excluded patients with diabetes mellitus, chronic kidney disease, cancer, chronic inflammatory diseases, high-grade chronic heart failure, and anemia. The examined sample was obtained through screening of 807 patients. All patients underwent a set of clinical, laboratory, and instrumental examinations, which included medical history collection (documented COVID-19 episodes, vaccination history, CAD exacerbations, treatment), cardiac ultrasound, endothelium-dependent vasodilation (EDVD) testing, general laboratory tests, and immunophenotyping of blood cell subpopulations by flow cytometry using the markers CD3, CD4, CD8, CD31, CD34, CD38, and CD309.Results. Patients in the examined groups did not differ in age or baseline clinical and anamnestic characteristics (including the frequency of documented COVID-19 and vaccination history), and all demonstrated high adherence to treatment. According to EDVD test, endothelial dysfunction was detected in 70 % of patients in both groups, and the mean test values were comparable. Biochemical blood parameters also showed no differences between the groups, nor did inflammatory markers such as C-reactive protein, erythrocyte sedimentation rate, the neutrophil-to-lymphocyte ratio, and the platelet-to-lymphocyte ratio. Correlation analysis of EDVD with inflammatory markers did not reveal any significant associations.However, immunophenotyping of blood cell subpopulations demonstrated significant differences between the groups. In group 2 patients, who had STEMI with concomitant COVID-19, lower levels of T lymphocytes and higher numbers of immature T-cell were observed, while the levels of T-helpers, T-suppressors, and their ratio did not differ from those in group 1. At the same time, the number of hematopoietic progenitor cells, activated T- and B-lymphocytes, as well as cells expressing vascular endothelial growth factor (VEGF) receptors, were increased. In this group, no significant correlations were found between EDVD results and any clinical, laboratory, or instrumental parameters, nor with the results of blood cell subpopulation phenotyping. When comparing subgroups of patients with markedly reduced endothelial function (values below the group mean), group 2 showed higher monocyte counts, lower lymphocyte counts, increased populations of activated T- and B-lymphocytes and immature T-lymphocytes, together with elevated levels of repair markers (CD309+ endothelial progenitors), while markers of endothelial activation and damage remained unchanged.Conclusions. A study conducted in a carefully selected cohort of patients with CAD who had previously experienced STEMI revealed the negative consequences of its combination with COVID-19. Despite similar clinical, instrumental, and laboratory characteristics between the groups, patients with concomitant COVID-19 demonstrated impaired mechanisms of endothelial function regulation and immune system dysfunction, characterized by the development of a pro-inflammatory cellular phenotype. These changes occurred against the background of vascular injury and were accompanied by secondary activation of proangiogenic reparative potential.
- Open Access
- 15 November 2025
- Published by Institute of Cell Therapy in Cell and Organ Transplantology
- Vol. 13 (2)
Optimized protocol for identifying senescence-associated heterochromatin foci (SAHF) as markers of cellular senescence in blood samples
Senescence-associated heterochromatin foci (SAHF) are distinct nuclear structures formed in senescent cells and involved in the permanent suppression of genes promoting cell proliferation. SAHF are composed of repressive chromatin marks and specific proteins. Their detection serves as a reliable hallmark of cellular senescence and holds potential clinical applications in aging research, cancer biology, regenerative medicine, and disease monitoring – including use as a marker of high cardiovascular risk in patients who have experienced acute cardiac conditions. This article reviews the current methods for SAHF detection in cultured cells and introduces an optimized protocol for identifying SAHF-positive cells in peripheral blood samples, which may facilitate non-invasive monitoring of senescence in vivo.
- 15 November 2025
- Published by Institute of Cell Therapy in Cell and Organ Transplantology
- Vol. 13 (2)
Open AccessOptimized protocol for identifying senescence-associated heterochromatin foci (SAHF) as markers of cellular senescence in blood samples
Senescence-associated heterochromatin foci (SAHF) are distinct nuclear structures formed in senescent cells and involved in the permanent suppression of genes promoting cell proliferation. SAHF are composed of repressive chromatin marks and specific proteins. Their detection serves as a reliable hallmark of cellular senescence and holds potential clinical applications in aging research, cancer biology, regenerative medicine, and disease monitoring – including use as a marker of high cardiovascular risk in patients who have experienced acute cardiac conditions. This article reviews the current methods for SAHF detection in cultured cells and introduces an optimized protocol for identifying SAHF-positive cells in peripheral blood samples, which may facilitate non-invasive monitoring of senescence in vivo.